Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2416-2422

  Ostorhazi, Eszter ^a   Rozgonyi, Ferenc ^a   Sztodola, Andras ^a   Harmos, Ferenc ^a   Kovalszky, Ilona ^a   Szabo, Dora ^a   Knappe, Daniel ^b   Hoffmann, Ralf ^b   Cassone, Marco ^c   Wade, John D ^d   Bonomo, Robert A ^e,f   Otvos Jr , Laszlo ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Temple University   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacterial counts; Burn injury; MDR Gram negative bacteria; Mouse models; Survival rate; Therapeutic index

Indexed keywords

COLISTIN; IMIPENEM; POLYPEPTIDE ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT A3 APO; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BLAST INJURY; BURN INFECTION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; LOW DRUG DOSE; MOUSE; NONHUMAN; WOUND HEALING;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BURNS; COLISTIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMIPENEM; INJECTIONS, INTRAMUSCULAR; MICE; PEPTIDES; PLASMA; TREATMENT OUTCOME; WOUND INFECTION;

EID: 77957870247     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq337     Document Type: Article

References (40)

1. Wurtz R, Karajovic M, Dacumos E et al. Nosocomial infections in a burn intensive care unit. Burns 1995; 21: 181-4.
2. Johnson EN, Burns TC, Hayda RA et al. Infectious complications of open type III tibial fractures among combat injuries. Clin Infect Dis 2007; 45: 409-15.
3. Petersen K, Riddle MS, Danko JR et al. Trauma-related infections in battlefield casualties in Iraq. Ann Surg 2007; 245: 803-11.
4. Murray CK, Wilkins K, Molter NC et al. Infections in combat casualties during Operations Iraqi and Enduring Freedom. J Trauma 2009; 66: S138-44.
5. Crane DP, Gromov K, Li D et al. Efficacy of colistin-impregnated beads to prevent multidrug-resistant A. baumannii implant-associated osteomyelitis. J Orthop Res 2009; 27: 1008-5.
6. Urban C, Segal-Murer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36: 1268-74.
7. Ganapathy H, Pal SK, Teare L et al. Use of colistin in treating multi-resistant Gram-negative organisms in a specialized burns unit. Burns 2010; 36: 522-7.
8. Hawley JS, Murray CK, Griffith ME. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 2007; 51: 376-8.
9. Rodriguez CH, De Ambrosio A, Bajuk M et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 2010; 29: 164-7.
10. Lin B, Zhang C, Xiao X. Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. J Vet Pharmacol Ther 2005; 8: 349-4.
11. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009; 69: 1879-901.
12. Sauermann R, Rothenburger M, Graininger W et al. Daptomycin: a review 4 years after first approval. Pharmacology 2007; 81: 79-91.
13. Rozgonyi F, Szabo D, Kocsis B et al. The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr Med Chem 2009; 16: 3996-4002.
14. Otvos L Jr, Wade JD, LinF et al. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J Med Chem 2005; 48: 5349-9.
15. Otvos L Jr, de Olivier Inacio V, Wade JD et al. Prior antibacterial peptide-mediated inhibition of protein folding in bacteria mutes resistance enzymes. Antimicrob Agents Chemother 2006; 50: 3146-9.
16. Cassone M, Vogiatzi P, La Montagna R et al. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics. Peptides 2008; 29: 1878-86.
17. Szabo D, Ostorhazi E, Binas A et al. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models. Int J Antimicrob Agents 2010; 35: 357-61.
18. Ostorhazi E, Rozgonyi F, Szabo D et al. Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections. Biopolymers 2010; doi:10.1002/bip.21443.
19. Noto PB, Abbadessa G, Cassone M et al. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci 2008; 17: 1249-55.
20. Bush K, Macielag M, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond Phase I. Curr Opin Microbiol 2004; 7: 466-76.
21. Yamakawa T, Mitsuyama J, Hayashi K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother 2002; 49: 455-65.
22. Tien HC, Battad A, Bryce EA et al. Multi-drug resistant Acinetobacter infections in critically injured Canadian forces soldiers. BMC Infect Dis 2007; 7: 95.
23. Griffith ME, Ceremuga JM, Ellis MW et al. Acinetobacter skin carriage among US army soldiers deployed in Iraq. Infect Control Hosp Epidemiol 2007; 28: 720-2.
24. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8: 687-93.
25. Boerlin P, Eugster S, Gaschen F et al. Transmission of opportunistic pathogens in a veterinary teaching hospital. Vet Microbiol 2001; 82: 347-59.
26. Morgan DJ, Liang SY, Smith CL et al. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns and hands of healthcare workers. Infect Control Hosp Epidemiol 2010; 31: 716-21.
27. Otvos L Jr. Antibacterial peptides and proteins with multiple cellular targets. J Pept Sci 2005; 11: 697-706.
28. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1: 156-64.
29. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
30. Wakabayashi H, Takase M, Tornita M. Lactoferricin derived from milk protein lactoferrin. Curr Pharm Res 2003; 9: 1277-87.
31. Zaleski KJ, Kolodka T, Cywes-Bentley C et al. Hyaluronic binding peptides prevent experimental staphylococcal wound infection. Antimicrob Agents Chemother 2006; 50: 3856-60.
32. Svenson J, Brandsdal B-O, Stensen W et al. Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J Med Chem 2007; 50: 3334-9.
33. Wang Y, Johansson J, Agerberth B et al. The antimicrobial peptide LL-37 binds to the human plasma protein apolipoprotein A-I. Rapid Commun Mass Spectrom 2004; 18: 588-9.
34. Ogata M, Fletcher MF, Kloczewiak M et al. Effects of anticoagulants on binding and neutralization of lipopolysaccharide by the peptide immunoglobulin conjugate CAP18106-138-immunoglobulin G in whole blood. Infect Immun 1997; 65: 2160-7.
35. Kragol G, Lovas S, Varadi G et al. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001; 40: 3016-26.
36. Jenssen H, Aspmo SI. Serum stability of peptides. In: Otvos L, ed. Peptide-Based Drug Design. Totowa: Humana Press, 2008; 177-86.
37. Powell MF, Grey H, GaetaF et al. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 1992; 81: 731-5.
38. Chertov O, Biragyn A, Kwak LW et al. Organic solvent extraction of proteins and peptides from serum as an effective preparation for detection and identification of biomarkers by mass spectrometry. Proteomics 2004; 4: 1195-203.
39. Cassone M, Otvos L Jr. Synergy among antimicrobial peptides and between peptides and small molecule antibiotics. Expert Rev Anti Infect Ther 2010; 8: 703-16.
40. Cassone M, Frith N, Vogiatzi P et al. Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK. Int J Pept Res Ther 2009; 15: 121-8.